407SC, Data and Systems Architect

Job Code 407SC


Fate Therapeutics is seeking an experienced Data and Systems Architect with biotechnology domain experience to develop and implement an innovative and flexible data strategy / architecture to enable the storage, organization, analysis and reporting of data in alignment with the scientific objectives across various business units supporting Fate’s growing pipeline of clinical programs. The successful candidate will collaborate extensively with research scientists, clinical data managers, data scientists/analysts, and vendor representatives and take an active role in developing and aligning data standards across the Company. This role will provide the thought leadership, facilitation, analysis, and design necessary to develop a robust data and information architecture focusing on clinical and translational research data, with the flexibility and scale appropriate vision to support multiple cross-functional business units and solutions. The successful candidate will balance multiple projects, analyze business trends and strategy, as well as change requirements to guide solution decisions. This is a fulltime position reporting to the Director, Information Technology and is located at our Company’s headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 407SC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.